Cervical cancer is the fourth most common cancer amongst women, accounting for approximately 6.5% of all female cancer cases globally. The Cancer Genome Atlas (TCGA) is a public funded project that aims to catalogue and discover major cancer-causing genomic alterations to create a comprehensive “atlas” of cancer genomic profiles. NFE2L2 is a gene which encodes for the transcription factor NRF2 (nuclear factor erythroid 2-related factor) which is the key regulator of oxidative stress in normal cells. Mutations in NFE2L2 gene have been identified across many cancers including cervical squamous cell carcinoma (CSCC) and the dysregulation of the NRF2 pathway due to these mutations leads to tumorigenesis, drug and radioresistance. Identification of biomarkers associated with these mutations allows the researchers and clinicians to identify the personalized medicine and quicker diagnosis. In our current study, we carried out an integrated, multi-omics, multi-database analysis of exome, transcriptomics data's of NFE2L2 mutated TCGA- Cervical squamous cell carcinoma patients against non-mutated counterparts. Finally, we discovered the genes associated with NFE2L2 mutations, identified the prognostic genes which could be used as potential biomarkers in the NFE2L2 mutated CSCC patients. Our finding might be useful to identify the early diagnosis of NFE2L2 mutated CSCC patients.
Previous Article in event Previous Article in session
Next Article in event Next Article in session
“Multi-omics analysis of NFE2L2 mutated TCGA-Cervical Squamous Cell Carcinoma patients”
Published: 16 March 2023 by MDPI in The 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies (IECC 2023) session Genome-wide Approaches for Target Identification.
Keywords: NFE2L2; Cervical cancer; multi-omics; biomarkers; therapeutic strategies
Supplementary material: Download Supplementary material View paper View Poster